ArticleJournal of translational medicine2026
Multi-omics and machine learning reveal DPPC as a key contributor to colorectal cancer progression and tumor immune microenvironment remodeling.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough previous studies have linked colorectal cancer (CRC) with lipid metabolism and inflammatory signaling, the specific roles of phosphatidylcholine metabolites and their interactions with inflammatory cytokines in the tumor microenvironment remain poorly understood.
methodsThis study utilizes an integrated multi-omics analysis approach. We performed a two-sample Mendelian randomization analysis using data from 1400 metabolites and 91 inflammatory cytokines to investigate their associations with CRC, followed by experimental validation of the findings. Single-cell transcriptomics revealed metabolic state differences, while machine learning constructed a predictive model. SHAP analysis interpreted the model, with spatial transcriptomics validating key findings.
resultsThe phosphatidylcholine metabolite DPPC was identified as causally associated with CRC risk. Our results demonstrated DPPC promotes tumor progression by inhibiting TNFSF14 secretion. Our DPPC-based model effectively predicted CRC progression, with SHAP analysis identifying ARL8A, MTUS1, and TMEM184A as key contributors. These findings were validated spatially and translated into a clinical nomogram for prognosis and immunotherapy guidance. In summary, this study highlights the significance of DPPC-mediated regulation within the tumor microenvironment in predicting CRC progression and guiding potential therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.